{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-003456","form_type":"8-K","ticker":null,"cik":"0001349929","company_name":"Vyant Bio, Inc.","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.576403+00:00","generated_at":"2026-06-20T00:53:36.449067+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vyant Bio cuts workforce, CEO and CSO depart; CFO takes over as company seeks sale or wind-down","bullets":["Board approved Cash Preservation Plan on Jan 31, including a reduction in force to retain only core employees.","Estimated severance and termination costs of ~$1.4M in Q1 and Q2 2023; reductions expected by end of February.","CEO John Roberts and CSO Robert Fremeau step down effective Feb 3; CFO Andrew LaFrence appointed President and CEO.","Company continues to explore strategic alternatives with LifeSci Capital, including sale, merger, or orderly wind-down.","Cash and cash equivalents ~$8.4M as of Jan 31, 2023; pre-clinical/clinical programs delayed or deferred."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-003456","json":"https://secwatch.observer/filing/0001493152-23-003456.json","markdown":"https://secwatch.observer/filing/0001493152-23-003456.md","text":"https://secwatch.observer/filing/0001493152-23-003456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:53:36.449067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40250f8359","claim":"Robert T. Fremeau, Jr. departed as Chief Scientific Officer at Vyant Bio, Inc..","evidence_excerpt":"John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"488ddecc27","claim":"John A. Roberts departed as President and Chief Executive Officer at Vyant Bio, Inc..","evidence_excerpt":"John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"713796087c","claim":"Andrew D.C. LaFrence changed role as President and Chief Executive Officer at Vyant Bio, Inc..","evidence_excerpt":"Andrew D.C. LaFrence, the Company’s Chief Financial Officer, will assume the role of President and Chief Executive Officer following Mr. Roberts’ departure.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assume"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"773c09fa2c43688e77f1364e74d2a7d098972138","claim":"Vyant Bio, Inc. announced a restructuring with charges of approximately $1.4 million.","evidence_excerpt":"the Board determined on January 31, 2023 to conduct a reduction in force as soon as practical, resulting in the retention of a core group of employees required for one or more potential strategic transactions and/or to execute an orderly wind down of the Company if required. The Company estimates that it will incur approximately $1.4 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.4 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}